Highly specific V3 peptide enzyme immunoassay for seretyping HIV-1 specimens from Thailand

Cp, Pau; S, Lee-Thomas; Auwanit, Wattana; George, .; Cy, Ou; Parekh, Bharat; Tc, Granade; Dl, Holloman; Phillips, Susan; Schochetman, Gerald

doi:10.1097/00002030-199303000-00005

Cited by 121 publications

(52 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lymphocyte immunophenotyping was done on fresh EDTAanticoagulated venous samples following the first seropositive visit with the FACScan flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, Calif.) using a standard six-tube, two-color monoclonal antibody panel (Becton Dickinson). A V3 peptide-based EIA was used to measure serum antibody reactivities to HIV-1 CRF01_AE and subtype B-specific V3 peptides (26,38).…”

Section: Methodsmentioning

confidence: 99%

Intersubtype Human Immunodeficiency Virus Type 1 Superinfection following Seroconversion to Primary Infection in Two Injection Drug Users

Ramos

Nguyen

et al. 2002

J Virol

Self Cite

161

122

View full text Add to dashboard Cite

In this study, we describe two cases of human immunodeficiency virus type 1 (HIV-1) intersubtype superinfection with CRF01_AE and subtype B strains, which occurred in two injection drug users participating in a prospective cohort study in Bangkok, Thailand. In both cases, the superinfecting strain was detected by molecular and serologic analyses several weeks after complete seroconversion to the primary infection with a strain belonging to a different subtype. Superinfection occurred despite specific T-cell and humoral antibody responses to the primary virus. In both cases, cross-subtype immune responses were limited or absent prior to the second infection. These data show that, in some individuals, the quality and quantity of the immune response elicited by primary HIV-1 infection may not protect against superinfection. This finding has important implications for vaccine design. HIV-1 vaccines, at a minimum, will need to include potent, broadly protective, conserved immunogens derived from several group M subtypes.

show abstract

Section: Methodsmentioning

confidence: 99%

Intersubtype Human Immunodeficiency Virus Type 1 Superinfection following Seroconversion to Primary Infection in Two Injection Drug Users

Ramos

Nguyen

et al. 2002

J Virol

Self Cite

161

122

View full text Add to dashboard Cite

show abstract

“…Plasma HIV RNA level determination was done by the NU-CLISENS method with a subset of four cohorts (n ϭ 124). Viral subtyping was performed by the Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand, by a peptide ELISA (30) and heteroduplex mobility assay (10). The 14 amino acids specific for subtype E (env subtype E; T S I T I G P G Q V F Y R T) and subtype B (env subtype B; K S I H L G P G Q A W Y T T) were used with the ELISA for this study.…”

Section: Methodsmentioning

confidence: 99%

A Double-Blind, Adjuvant-Controlled Trial of Human Immunodeficiency Virus Type 1 (HIV-1) Immunogen (Remune) Monotherapy in Asymptomatic, HIV-1-Infected Thai Subjects with CD4-Cell Counts of >300

Churdboonchart¹,

Sakondhavat

Kulpradist

et al. 2000

Clin Diagn Lab Immunol

View full text Add to dashboard Cite

We examined the effect of a human immunodeficiency virus (HIV)-specific immune-based therapy in Thailand, where access to antiviral drug therapy is limited. A 40-week trial was conducted with 297 asymptomatic, HIV-infected Thai subjects with CD4-cell counts greater than 300 l/mm 3 . Subjects were randomized to receive either HIV type 1 (HIV-1) immunogen (Remune; inactivated HIV-1 from which gp120 is depleted in incomplete Freund's adjuvant or adjuvant control at 0, 12, 24, and 36 weeks at five different clinical sites in Thailand. Neither group received antiviral drug therapy. The a priori primary endpoint for the trial was changes in CD4-cell counts with secondary parameters of percent changes in CD8-cell counts (percent CD4, CD8, and CD4/CD8) and body weight. Subsets of subjects were also examined for changes in plasma HIV-1 RNA levels, Western blot immunoreactivity, and HIV-1 delayed-type hypersensitivity (DTH) skin test reactivity. There was a significant difference in changes in CD4-cell counts that favored the HIV-1 immunogen-treated group compared to those for the adjuvant-treated control group (P < 0.05). On average, for HIV-1 immunogentreated subjects CD4-cell counts increased by 84 cells by week 40, whereas the increase for the control group was 38 cells by week 40. This increase in CD4-cell count was associated with increased HIV-specific immunogenicity, as shown by Western blotting and enhanced HIV-1 DTH skin reactivity. No significant differences in adverse events were observed between the groups. The results of this trial suggest that HIV-1 immunogen is safe and significantly increases CD4-cell counts and HIV-specific immunity compared to those achieved with the adjuvant control in asymptomatic HIV-1-infected subjects not taking antiviral drugs.

show abstract

“…Endpoint titers were determined using twofold dilutions. Antigen preparation, plate coating, and ELISA methods were as described previously (22). The assay cutoff was the mean corrected optical density at 450 nm (OD 450 ) of five pools of negative control sera plus 0.150 OD units.…”

Section: Methodsmentioning

confidence: 99%

Evidence for both Lytic Replication and Tightly Regulated Human Herpesvirus 8 Latency in Circulating Mononuclear Cells, with Virus Loads Frequently below Common Thresholds of Detection

Martró

Cannon²,

Dollard³

et al. 2004

J Virol

Self Cite

View full text Add to dashboard Cite

To address whether human herpesvirus 8 (HHV-8) DNA in peripheral blood mononuclear cells (PBMCs) might be the product of latent or lytic infection and to shed light on sporadic detection of HHV-8 DNA in individuals seropositive for the virus, we studied the frequency of infected cells, total virus load, and virus load per infected cell in PBMCs from men coinfected with HHV-8 and human immunodeficiency virus (HIV), some of whom had Kaposi's sarcoma. The low frequencies of infected cells detected (fewer than one per million cells in some individuals) suggest that the prevalence of the virus in circulating leukocytes was underestimated in previous studies that employed more conventional sampling methods (single, small-volume specimens). Mean virus loads ranged from 3 to 330 copies per infected PBMC; these numbers can represent much higher loads in individual lytically infected cells (>10 3 genomes/cell) in mixtures that consist predominantly of latently (relatively few genomes) infected cells. The presence in some subjects of high HHV-8 mean genome copy numbers per infected cell, together with viral DNA being found in plasma only from subjects with positive PBMCs, supports earlier suggestions that the virus can actively replicate in PBMCs. In some individuals, mean virus loads were less than 10 genomes per infected cell, suggesting a tightly controlled purely latent state. HHV-8 genome copy numbers are substantially higher in latently infected cells derived from primary effusion lymphomas; thus, it appears that HHV-8 is able to adopt more than one latency program, perhaps analogous to the several types of Epstein-Barr virus latency.

show abstract

Highly specific V3 peptide enzyme immunoassay for seretyping HIV-1 specimens from Thailand

Cited by 121 publications

References 0 publications

Intersubtype Human Immunodeficiency Virus Type 1 Superinfection following Seroconversion to Primary Infection in Two Injection Drug Users

Intersubtype Human Immunodeficiency Virus Type 1 Superinfection following Seroconversion to Primary Infection in Two Injection Drug Users

A Double-Blind, Adjuvant-Controlled Trial of Human Immunodeficiency Virus Type 1 (HIV-1) Immunogen (Remune) Monotherapy in Asymptomatic, HIV-1-Infected Thai Subjects with CD4-Cell Counts of >300

Evidence for both Lytic Replication and Tightly Regulated Human Herpesvirus 8 Latency in Circulating Mononuclear Cells, with Virus Loads Frequently below Common Thresholds of Detection

Contact Info

Product

Resources

About